All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
BESRA is a national, multi-center, prospective, observational study to assess the effectiveness of brolucizumab intravitreal injections in patients with nAMD treated in the UK.
Neovascular Age-related Macular Degeneration
Nov 19, 2021
Sep 01, 2027
50 Years and older (Adult, Older Adult)
There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
Diagnosis of nAMD
≥50 years of age at index date
Receipt of at least one injection of brolucizumab during the eligibility period
Able and willing to provide signed informed consent
Received treatment for retinal vein occlusion, diabetic macular edema (DME) and/or myopic choroidal neovascularization (mCNV), and/or has received a new diagnosis of diabetes-related macular degeneration in the index eye within 6 months prior to the index date
Receipt of anti-VEGF treatment other than brolucizumab in the index eye at index date
Any active intraocular or periocular infection or active intraocular inflammation in the index eye at index date
Has been on anti-VEGF treatment for longer than 3 years (before index date)
Has a contraindication and is not eligible for treatment with brolucizumab according to the Beovu® (brolucizumab) Summary of Product Characteristics (SmPC) ("Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)" 2020)
Any medical or psychological condition in the treating physician's opinion which may prevent the patient from participating in the study
Participating in a parallel interventional clinical study
Participating in a parallel non-interventional study (NIS) generating primary data for an anti- VEGF drug.